HTD1801 Significantly Improves Blood Sugar and Cardiometabolic Health in Type 2 Diabetes Read more about HTD1801 Significantly Improves Blood Sugar and Cardiometabolic Health in Type 2 Diabetes
Tirzepatide Drives Significant Weight Loss and Insulin Reduction in Type 1 Diabetes Read more about Tirzepatide Drives Significant Weight Loss and Insulin Reduction in Type 1 Diabetes
Semaglutide and Cagrilintide Combination Achieves Dramatic Weight Loss in Type 2 Diabetes Tags SGLT-2 Inhibitor Read more about Semaglutide and Cagrilintide Combination Achieves Dramatic Weight Loss in Type 2 Diabetes
Fully Human Anti-Thymocyte Antibody Shows Favorable Safety in Early T1D Trial Read more about Fully Human Anti-Thymocyte Antibody Shows Favorable Safety in Early T1D Trial
SGLT2 Inhibitors Outperform GLP-1RAs in Preserving Kidney Function in T2D Tags Diabetic Nephropathy SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Outperform GLP-1RAs in Preserving Kidney Function in T2D
Fixed-Dose Empagliflozin/Linagliptin Shows Superior HbA1c Reduction with Metformin Tags DPP-4 inhibitors SGLT-2 Inhibitor Read more about Fixed-Dose Empagliflozin/Linagliptin Shows Superior HbA1c Reduction with Metformin
Injection-Free Exenatide Device Shows Strong HbA1c Reductions in Poorly Controlled T2DM Read more about Injection-Free Exenatide Device Shows Strong HbA1c Reductions in Poorly Controlled T2DM
Meta-Analysis Confirms GLP-1 Therapy Improves Outcomes in Obese Patients With HFpEF Read more about Meta-Analysis Confirms GLP-1 Therapy Improves Outcomes in Obese Patients With HFpEF
Higher-Dose Semaglutide (7.2 mg) Yields Drives Greater Weight and Glycemic Benefits in T2D Read more about Higher-Dose Semaglutide (7.2 mg) Yields Drives Greater Weight and Glycemic Benefits in T2D
SGLT2 Inhibitors Linked to Lower Age-Related Macular Degeneration Risk Tags SGLT-2 Inhibitor Read more about SGLT2 Inhibitors Linked to Lower Age-Related Macular Degeneration Risk